Dermatology

RT @Gibson_RheumPAC Drug-induced SCLE remains an important mimic in biologic-treated patients. Compared with idiopathic SCLE, drug-induced disease is often more widespread and may resolve with antibody normalization after withdrawal.#RNL26 https://t.co/ICOzg3Tz4L
Dr. John Cush @RheumNow( View Tweet )
RT @Gibson_RheumPAC Important rheumatology signal: dupilumab-associated inflammatory arthritis. Usually seronegative, imaging-supported, and sometimes persistent despite normal labs. Co-management and careful work-up are essential.#RNL26 https://t.co/r73cSZC59s
Dr. John Cush @RheumNow( View Tweet )
RT @@Gibson_RheumPAC Eczematous eruptions with IL-17 inhibition are increasingly recognized. Registry data suggest higher adjusted incidence with IL-17 inhibitors compared with other biologic classes, especially in older patients and those with atopic history. #RNL26 https://t.co/nvwl5mNg4k
Dr. John Cush @RheumNow( View Tweet )
RheumNow Podcast square

Maui Potpourri (2.13.2026)

Jack Cush, MD

Dr. Jack Cush reviews the hot item takeaways from last week's RheumNow.Live 2026.

  1. Diet & Obesity Management in Rheumatology - Uzma Haque, MD
  2. Mitigating risk for Rheum patients undergoing orthopedic surgery - Susan Goodman, MD
  3. Paradoxical skin reactions – Joseph
Read Article
Always on exams, but I've never seen a case! JAMA Dermatology reviews Multicentric Reticulohistiocytosis - pt w/ multiple nodules on hands & pain in shoulders, elbows, MCPs, IPs. Erythema over face, chest, & back & bead like Perionychial papules. Rx w/ MTX + Pred https://t.co/QgS5VBOB51
Dr. John Cush @RheumNow( View Tweet )
RheumNow Podcast square

ANA Pollution (2.06.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal articles and regulatory news from this past week on RheumNow.com

Read Article
DERM on RheumNow PODCAST (January 2026) The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and https://t.co/nX0iWp2J0I
Dr. John Cush @RheumNow( View Tweet )
Morphea,crop

DMARD Responses in Localized Scleroderma

Jack Cush, MD

JAMA Dermatology has published the results of a juvenile localized scleroderma (JLS) trial showing that mycophenolate mofetil (MMF) and methotrexate (MTX) are equally effective in treating JLS, noting low flare rates and possibly better tolerability with MMF.

Read Article
New content online: Recommendations for the use of CLASI as an outcome measure in cutaneous lupus erythematosus clinical trials https://t.co/nDxfWWgutC https://t.co/Z6JMojdBz4

Links:

NatRevRheumatol @NatRevRheumatol( View Tweet )
Turkish study of 128 Psoriatics (62 PSO, 66 PsA) found more periodontitis in PsA vs PSO (47% vs 31%; P=.058). Signif. higher levels of Dz activity seen for PSO (CPDAI: OR 1.38; P = .001) & enthesitis (MASES: OR 1.39; P < .001) if periodontitis present in PsA patients. https://t.co/d8OfarFWeG
Dr. John Cush @RheumNow( View Tweet )
RheumNow Podcast square

Emergencies, Independence & Hemorrhage (1.23.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news and reports from the past two weeks on RheumNow.Com

Read Article
French Retrospective study (2011-22) of 36129 adult psoriasis pts on biologics who recv antibiotics (9366/26% @ baseline, 61% during FU). Abx treatment assoc w/ 12% greater risk biologic D/C (HR 1.12); more for multiple Abx courses (HR 1.29; 95% CI, 1.24-1.35) https://t.co/2Jv5xCibyd
Dr. John Cush @RheumNow( View Tweet )
Advanced Practitioner Biologic Prescriptions for Psoriasis Advanced practice clinicians (APCs; nurse practitioners and physician assistants) deliver a large share of US dermatologic care, accounting for 37% of clinicians and 27% of dermatology visits by 2020. A current JAMA https://t.co/3NtntmpSPV
Dr. John Cush @RheumNow( View Tweet )
Spread of Psoriatic Disease from Skin to Joints Approximately 20-30 % of all people who suffer from psoriasis also develop painful inflammation in their joints over time. If left untreated, PsA can lead to permanent damage to bones and joints. Why the disease progresses was https://t.co/UbGHFASKvc
Dr. John Cush @RheumNow( View Tweet )
PSO.Palmoplantar.jpg

Advanced Practitioner Biologic Prescriptions for Psoriasis

Jack Cush, MD

Advanced practice clinicians (APCs; nurse practitioners and physician assistants) deliver a large share of US dermatologic care, accounting for 37% of clinicians and 27% of dermatology visits by 2020. A current JAMA Dermatology reports APC drug spending trends in dermatology, with a focus on

Read Article
T%20cell.jpg

Spread of Psoriatic Disease from Skin to Joints

Jack Cush, MD

Approximately 20 to 30 percent of all people who suffer from psoriasis also develop painful inflammation in their joints over time. If left untreated, psoriatic arthritis can lead to permanent damage to bones and joints. Why the disease progresses was assessed by researchers from the

Read Article
lupus SLE

Subcutaneous Anifrolumab in SLE

Jack Cush, MD

Manzi et al. have published the results of the TULIP-SC trial that showed that weekly subcutaneous (SC) anifrolumab, when given to severe SLE patients, had comparable efficacy and safety to the approved intravenous (IV) anifrolumab. 

TULIP-SC was a

Read Article
Best of 2025: 2025 BSR Guideline for Treatment of Axial Spondyloarthritis The British Society of Rheumatology's 2025 Guidelines for treating axSpa focus on both axial and extra-musculoskeletal issues like uveitis, psoriasis, and IBD. They evaluate the effectiveness and safety of https://t.co/8VNQtP3Izj
Dr. John Cush @RheumNow( View Tweet )
DERM on RheumNow Podcast (December 2025) https://t.co/icOauEOhLP https://t.co/eMt40WFiFD

Links:

Dr. John Cush @RheumNow( View Tweet )
obese.waist_.jpg

GLP-1 Agonist plus IL-17 Inhibition in Obese Psoriatic Arthritis

Jack Cush, MD

Lilly announced the topline results from its phase 3b "TOGETHER PsA" trial, showing that the combination use of ixekizumab (Taltz) and tirzepatide (Zepbound) was superior to IXE alone, yielding both significant weight loss and ACR50 disease control in adults with active psoriatic arthritis (PsA

Read Article
JAMA teaching case: 57 yoF w/ RA Rx w/ HCQ, NSAID, TNFi (ETN -->ADA) develops a new rash - pruritic vesicles/papular on neck, mouth, ears, chest, hands w/ some becoming ulcerated plaques, ESR >100. WHAT TO DO? A) steroids; B) stop ADA; C) Benadryl or D) Read more? Pt had https://t.co/DQpeUOC5I3
Dr. John Cush @RheumNow( View Tweet )
Best of 2025: Dermatomyositis Reviewed Researchers from the University of Pennsylvania have published an open-access review of dermatomyositis (DM) - its manifestations, hallmark cutaneous features, etiopathogenesis and treatment options. https://t.co/0vDvqIcj6U https://t.co/ogPjPI5gJa

Links:

Dr. John Cush @RheumNow( View Tweet )
Lancet review of skin cancer risk w/ inflammatory arthritis - both melanoma and Non-melanoma skin cancers are increased in RA & inflammation. Also Package inserts for TNFi say all TNFi Rx pts should have complete skin exams "periodically". Skin cancer screening advised. https://t.co/XddFDe0xh8
Dr. John Cush @RheumNow( View Tweet )
RheumNow Podcast square

Telling You Where to Go (12.19.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. Who would've thunk - a PsA FMF connection? Labs to diagnose SSc-ILD? IgA-RF may be important or RZV may not work in JAK inhibitor treated patients?

Read Article
Lancet review of skin cancer risk w/ inflammatory arthritis - both melanoma and Non-melanoma skin cancers are increased in RA & inflammation. Also Package inserts for TNFi say all TNFi Rx pts should have complete skin exams "periodically". Skin cancer screening advised. https://t.co/MNuQO6Dw5b
Dr. John Cush @RheumNow( View Tweet )

Recent Blogs

A Domain-Based Approach to the GRAPPA Psoriatic Arthritis Treatment Recommendations

Laura Coates
heel enthesitis spur calcaneal

With their publication in June 2022 (1), the 3rd iteration of the Group for Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Treatment recommendations for Psoriatic Arthritis (PsA) may have set a record or sorts.

Read Post

Pain in Psoriatic Arthritis

Philip Mease, MD
backpain.hip_.jpg (keep)
Pain is typically ranked by both patients and physicians as the most important symptom of psoriatic arthritis (PsA) to assess and treat. Although the predominant concept of the etiology of pain in PsA is that of inflammation in peripheral joints, entheses, and bone signaling through peripheral nociceptive fibers, perceived as pain in the central nervous system, it is actually more complex than that. The ability of a treatment to ameliorate pain is one of the principle measures of its effectiveness. Thus pain improvement or worsening are key determinants of shared decision making about treatment in PsA.  Read Post
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

Rx Updates (filtered for Topic)

Therapeutic Updates

The Impact of Obesity on Psoriatic Arthritis

Sponsored by Lilly Medical Affairs
Lilly February RX Update Revised Image
Image alt text: A person indoors raises one arm in a flexed pose while holding the elbow with the opposite hand. Is obesity common in your patients with PsA? Learn more about the intersection of disease pathogenesis between PsA and obesity and how weight intervention can affect PsA outcomes.
Read Post
×